141 research outputs found
The percutaneous assessment of regional and acute coronary hot unstable plaques by thermographic evaluation (PARACHUTE) study: A prospective reproducibility and prognostic clinical study using thermography to predict future ischemic cardiac events
Intravascular thermography is currently being considered as a valuable tool in assessing macrophage-rich plaques. Since it is unknown what the prognostic value is of non-obstructive atherosclerotic plaques showing temperature heterogeneity, we designed the PARACHUTE study, a prospective, reproducibility, and prognostic clinical study using thermography in patients presenting with an unstable coronary syndrome. The primary endpoint of the study is the predictive value of temperature heterogeneity towards the occurrence of ischemic coronary events and hospitalization for ischemia and/or angina. The secondary endpoints are the predictive value of high-risk plaques associated with the development of future cardiac events, assessmen
Intracoronary adenosine-induced torsades de pointes during fractional flow reserve measurement
TCT-38 Two-Year Clinical Data Of Cohort 1 And Multi-Modality Imaging Results Up To 1-Year Follow-Up Of The BIOSOLVE-I Study With The Paclitaxel-Eluting Bioabsorbable Magnesium Scaffold (DREAMS)
TCT-657 Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment Evaluation Of Elixir DESyneTM Novolimus-Eluting Coronary Stent System With Durable Polymer To Endeavor Zotarolimus-Eluting Coronary Stent System: 3-Year Clinical and 9-Month Angiographic And IVUS Results: EXCELLA II Study
Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure : first-inman experience with the V-Wave device
Aims: Elevated filling pressures of the left atrium (LA) are associated with poorer outcomes in patients with
chronic heart failure. The V-Wave is a new percutaneously implanted device intended to decrease the LA
pressure by the shunting of blood from the LA to the right atrium. This report describes the first-in-man experience
with the V-Wave device.
Methods and results: A 70-year-old man with a history of heart failure of ischaemic origin, left ventricular
dysfunction (LVEF: 35%, pulmonary wedge: 19 mmHg), no right heart dysfunction, NYHA Class III and
orthopnoea despite optimal treatment, was accepted for V-Wave device implantation. The device consists of
an ePTFE encapsulated nitinol frame that is implanted at the level of the interatrial septum and contains
a trileaflet pericardium tissue valve sutured inside which allows a unidirectional LA to right atrium shunt. The
procedure was performed through a transfemoral venous approach under fluoroscopic and TEE guidance.
The device was successfully implanted and the patient was discharged 24 hours after the procedure with no
complications. At three-month follow-up a left-to-right shunt through the device was confirmed by TEE. The
patient was in NYHA Class II, without orthopnoea, the Kansas City Cardiomyopathy index was 77.6 (from
39.1 at baseline) and NT-proBNP was 322 ng/mL (from 502 ng/mL at baseline). The QP/QS was 1.17 and the
pulmonary wedge was 8 mmHg, with no changes in pulmonary pressure or right ventricular function.
Conclusions: Left atrial decompression through a unidirectional left-to-right interatrial shunt represents a new
concept for the treatment of patients with left ventricular failure. The present report shows the feasibility of
applying this new therapy with the successful and uneventful implantation of the V-Wave device, which was
associated with significant improvement in functional, quality of life and haemodynamic parameters at 90 days
Influence of intracoronary attenuation on coronary plaque measurements using multislice computed tomography: Observations in an ex vivo model of coronary computed tomography angiography
Assessment of attenuation (measured in Hounsfield units, HU) of human coronary plaques was performed using multislice computed tomography (MSCT) in an ex vivo model. In three ex vivo specimens of left coronary arteries in oil, MSCT was performed after intracoronary injection of four solutions of contrast material (400 mgI/ml iomeprol). The four solutions were diluted as follows: 1/∞, 1/200, 1/80, and 1/20. All scans were performe
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial
ObjectivesThe aim of this study was to compare, in a randomized multicenter trial, paclitaxel-eluting stents (CoStar, Conor Medsystems, Menlo Park, California) versus pimecrolimus-eluting stents (Corio, Conor Medsystems) versus stents with dual elution of both drugs (SymBio, Conor Medsystems) in native coronary arteries.BackgroundThe CoStar cobalt-chromium reservoir-based stent platform, eluting paclitaxel in a controlled way via a bioresorbable polymer, reduces restenosis versus its respective bare-metal stent. The reservoir system allows the use of other drugs targeted to different mechanisms involved in the process of vascular restenosis and simultaneous loading of multiple, synergistic drugs.MethodsPatients with single de novo lesions were asymmetrically randomized to 1 of the 3 types of stent (1:2:2). Six-month coronary angiography was planned in all. The primary analysis was a noninferiority test for the primary end point of 6-month angiographic in-stent late lumen loss of Corio versus CoStar and SymBio versus CoStar. Secondary end points included binary angiographic restenosis and major adverse clinical events (cardiac death, myocardial infarction, target vessel revascularization).ResultsThe trial was prematurely suspended after 246 patients were enrolled (planned enrollment: 375 patients): 49 patients received CoStar, 97 received SymBio, and 100 received Corio. In-stent late loss was significantly reduced with CoStar versus either SymBio or Corio (0.58 ± 0.58 mm vs. 0.96 ± 0.73 mm and 0.58 ± 0.58 mm vs. 1.40 ± 0.67 mm, p < 0.001 for both comparisons). Binary in-stent restenosis rates were, 7.1%, 20%, and 40.9%, respectively (p < 0.001 for both comparisons); 6-month major adverse cardiac event rates were, 2.0%, 14.4%, and 39.0%, respectively (p < 0.001 for both comparisons).ConclusionsStents eluting pimecrolimus or the dual combination of pimecrolimus and paclitaxel failed to show angiographic noninferiority when compared with paclitaxel-eluting stents. (A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems; NCT00322569
TCT-17 Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 3-Year Clinical and Imaging Results
TCT-37 Prospective, Multi-Center Evaluation of the DESolve Nx Novolimus-Eluting Bioresorbable Coronary Scaffold: First Report of One Year Clinical and Imaging Outcomes
- …